Tehcnology group Halma has announced the acquisition of French company Lamidey Noury Medical in a deal worth £42m.

The consideration, on a cash and debt-free basis, will be funded from Halma’s existing facilities.

Headquartered close to Paris, Lamidey Noury manufactures advanced electrosurgical and associated energy devices which are used in minimally invasive urology, gynaecology, and general surgery. Its products are sold to healthcare providers in over 60 countries.

Lamidey Noury’s unaudited revenue for the 12 months to October was £11.4m, with an EBIT margin above the upper end of Halma’s target range of 19-23%. The group will be a standalone company within Halma’s healthcare Sector, led by its current management team.

Group chief executive of Halma, Marc Ronchetti, commented: “Lamidey Noury is an exciting acquisition which will bring new minimally invasive surgical product capabilities to our Healthcare Sector.

“It is adjacent to our existing presence in diagnosis and biopsy devices for these diseases through Rovers Medical Devices and IZI Medical. We are delighted to welcome Lamidey Noury to Halma and look forward to supporting its development as it continues to scale its business globally.”

President of Lamidey Noury, Guillaume Noury, added: “Joining Halma is an exciting opportunity for us. Leveraging Halma’s expertise, resources, and global reach will accelerate our growth and innovation.

“We are confident in our ability to continue delivering high-quality surgical tools to our customers worldwide, while providing new opportunities for our employees and stakeholders. Together, we will continue improving patient outcomes and driving excellence in healthcare.”

---